Terns Pharmaceuticals Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
59
- Stock Symbol
-
TERN
- Investments
-
1
- Share Price
-
$2.92
- (As of Friday Closing)
Terns Pharmaceuticals General Information
Description
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
Contact Information
Website
www.ternspharma.comCorporate Office
- 1065 East Hillsdale
- Suite 100
- Foster City, CA 94404
- United States
Corporate Office
- 1065 East Hillsdale
- Suite 100
- Foster City, CA 94404
- United States
Terns Pharmaceuticals Stock Performance
As of 25-Apr-2025, Terns Pharmaceuticals’s stock price is $2.92. Its current market cap is $255M with 87.3M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.92 | $3.05 | $1.86 - $11.40 | $255M | 87.3M | 1.33M | -$1.12 |
Terns Pharmaceuticals Financials Summary
As of 31-Dec-2024, Terns Pharmaceuticals has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 99,089 | 99,089 | 135,216 | 318,157 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (100,986) | (100,986) | (101,991) | (61,065) |
| Net Income | (88,853) | (88,853) | (90,210) | (60,345) |
| Total Assets | 363,929 | 363,929 | 268,517 | 287,026 |
| Total Debt | 1,347 | 1,347 | 603 | 1,205 |
Terns Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Terns Pharmaceuticals Comparisons
Industry
Financing
Details
Terns Pharmaceuticals Competitors (88)
One of Terns Pharmaceuticals’s 88 competitors is Akero Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Akero Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Regulus Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| AVEO Oncology | Formerly VC-backed | Boston, MA | ||||
| Intercept Pharmaceuticals | Formerly VC-backed | Morristown, NJ | ||||
| Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA |
Terns Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Terns Pharmaceuticals Patents
Terns Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250090530-A1 | Combinations for the treatment of cancer | Pending | 31-Aug-2023 | ||
| US-20240398794-A1 | Combinations of glp-1r and thrß agonists and methods of use thereof | Pending | 07-Apr-2023 | ||
| US-20240368120-A1 | Compounds as glp-1r agonists | Pending | 29-Mar-2023 | ||
| US-20240360122-A1 | Polymorphic forms and salts of a glp-1r agonist | Pending | 29-Mar-2023 | ||
| US-20230322758-A1 | Compounds as glp-1r agonists | Pending | 23-Feb-2022 | C07D417/14 |
Terns Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Terns Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Terns Pharmaceuticals Investments (1)
Terns Pharmaceuticals’s most recent deal was a Corporate Asset Purchase with Eli Lilly (Rights to Three NASH Assets). The deal was made on 04-Apr-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Eli Lilly (Rights to Three NASH Assets) | 04-Apr-2018 | Corporate Asset Purchase | Buildings and Property |
Terns Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 30, 2024
37.42 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,109
Rank
Percentile
Pharmaceuticals
Industry
of 861
Rank
Percentile
Biotechnology
Subindustry
of 371
Rank
Percentile
Terns Pharmaceuticals FAQs
-
When was Terns Pharmaceuticals founded?
Terns Pharmaceuticals was founded in 2016.
-
Where is Terns Pharmaceuticals headquartered?
Terns Pharmaceuticals is headquartered in Foster City, CA.
-
What is the size of Terns Pharmaceuticals?
Terns Pharmaceuticals has 59 total employees.
-
What industry is Terns Pharmaceuticals in?
Terns Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Terns Pharmaceuticals a private or public company?
Terns Pharmaceuticals is a Public company.
-
What is Terns Pharmaceuticals’s stock symbol?
The ticker symbol for Terns Pharmaceuticals is TERN.
-
What is the current stock price of Terns Pharmaceuticals?
As of 25-Apr-2025 the stock price of Terns Pharmaceuticals is $2.92.
-
What is the current market cap of Terns Pharmaceuticals?
The current market capitalization of Terns Pharmaceuticals is $255M.
-
Who are Terns Pharmaceuticals’s competitors?
Akero Therapeutics, Regulus Therapeutics, AVEO Oncology, Intercept Pharmaceuticals, and Dicerna Pharmaceuticals are some of the 88 competitors of Terns Pharmaceuticals.
-
What is Terns Pharmaceuticals’s annual earnings per share (EPS)?
Terns Pharmaceuticals’s EPS for 12 months was -$1.12.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
